Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not met at 24 weeks Overall, DNL343 was found to be safe ...
Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not met at 24 weeks Overall, DNL343 was found to be safe and ...
Zacks.com on MSN17d
Denali's ALS Study Fails to Meet Primary and Secondary EndpointsDNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis of Regimen G of the phase II/III HEALEY ALS platform trial.
DNL343 showed no significant difference in ALSFRS-R scores or secondary endpoints compared to placebo over 24 weeks. Analysts await late-2025 data on biomarkers and subgroup findings for DNL343 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback